


Coronary Artery Calcium: Clinical Risk and the Athletic Paradox

Moving from Probabilistic Models to Individualized Disease Visualization



Executive Synthesis



The Paradigm Shift

Moving beyond surrogate markers (cholesterol/BP) to direct visualization of atherosclerotic burden via Coronary Artery Calcium (CAC) scoring.




The Methodology

Utilizing non-contrast, ECG-gated CT and the Agatston scoring method to quantify calcified plaque volume and density.




The 'Power of Zero' & Limits

Agatston 0 implies low near-term risk in asymptomatic patients but does not rule out non-calcified plaque in symptomatic individuals.



The Athletic Paradox

Evidence from Master@Heart reveals lifelong endurance athletes often exhibit higher plaque burdens than sedentary controls, challenging the linear "exercise = heart health" model.



From Probability to Visualization

Old Paradigm: Probabilistic Models



Basis: Indirect surrogate markers (Cholesterol, Blood Pressure, Diabetes).

Limitation: Estimates likelihood based on population averages, often misclassifying individual risk.

New Paradigm: Disease-Based Imaging




Basis: Direct visualization of atherosclerotic burden.

Advantage: Highly individualized risk stratification based on actual presence of disease.

Key Insight: CAC is a robust, independent predictor of myocardial infarction and cardiovascular mortality, outperforming traditional risk factors alone (Parikh et al., 2018).

CAC is an Active Biological Process

Iceberg Analogy



The presence of calcium generally implies a larger underlying burden of both calcified and non-calcified disease.

Definition


Coronary calcification is a regulated process, not a passive accumulation of minerals. It indicates the presence of advanced atherosclerosis.

Source

Blaha et al., 2023;
Parikh et al., 2018.


The Mechanics of Acquisition

- **Technique:** Non-contrast, ECG-gated Computed Tomography (CT).
- **Hardware Evolution:** Modern Multidetector CT (MDCT) has replaced Electron Beam CT (EBCT) due to higher spatial resolution and availability.




Calculating the Agatston Score

Score =



Lesion Area
(≥ 130 HU, $\geq 1\text{mm}^2$)

×



Density Factor
(1–4)

Density Factors:

130–199 HU = Factor 1


200–299 HU = Factor 2

300–399 HU = Factor 3

≥ 400 HU = Factor 4

Total Score is the sum of scores across the Left Main, LAD, LCx, and RCA.


Safety, Radiation, and Scope



- **Radiation Profile:**
Generally low dose.
Typical contemporary protocols:
~1 mSv under optimized conditions.
- **Clinical Implication:**
The scan captures extracardiac structures.
Incidental findings are common and may require downstream testing.


Source: Kim et al., 2009; Hecht et al., 2024.

Predictive Power and Risk Reclassification



Primary Application: Refines risk assessment for patients in the "gray zone" where statin decisions are unclear. Validated by the Multi-Ethnic Study of Atherosclerosis (MESA).

The Prognostic "Power of Zero"



- **Definition:**
Agatston Score = 0
(No detectable calcified plaque).
- **Meaning:**
Associated with very low short-to-intermediate-term event rates in ASYMPTOMATIC adults.
- **Action:** Often supports downward risk reclassification.

Source: Grundy et al., 2019; Hecht et al., 2024.

The Dangerous Gap: Why Zero $\neq$ Immunity

CONFIRM Registry Data: Symptomatic Patients with CAC=0


13% had nonobstructive CAD **13%**

3.5% had $\geq 50\%$ stenosis


1.4% had $\geq 70\%$ stenosis

In symptomatic patients, CAC=0 is NOT a definitive rule-out. It misses non-calcified (soft) plaque. Younger symptomatic patients are more likely to have non-calcified disease.

Villines et al., 2011; Mortensen et al., 2022.



The Paradox of the Endurance Athlete



The Expectation:
Exercise = Heart Health

The Reality:
Masters athletes (>35y, high intensity) frequently exhibit higher CAC prevalence and plaque burden than sedentary controls



Evidence from the Master@Heart Cohort



Control / Sedentary



Lifelong Endurance

Lifelong endurance exercise is associated with higher coronary atherosclerosis burden.

Superior fitness does not grant immunity to plaque accumulation.

High fitness does not shield against the formation of plaque.

De Bosscher et al., 2023.

Interpreting the Athlete's Risk



The Nuance:

Despite higher CAC scores, outcomes in athletes are often favorable due to physiological buffers.

CLINICAL WARNING: Do NOT dismiss high CAC in an athlete as 'benign'. It represents real atherosclerosis and demands risk factor management.

Selecting the Right Tool: CAC vs. CCTA

CAC (Non-Contrast CT)	CCTA (Angiography)
	
Best For Asymptomatic Risk Stratification	Best For Symptomatic Evaluation (Chest Pain)
✓ Pros: Low radiation, No contrast, Low cost. ✗ Cons: Misses non-calcified plaque.	✓ Pros: Visualizes soft plaque & obstruction. ✗ Cons: Requires contrast, higher complexity.


The Future of Imaging



Hardware

Photon-Counting CT (PCCT)

Emerging detector technology with higher resolution. Reduces "blooming" artifacts for precise quantification.



Software

AI-Enabled Quantification

Deep learning analysis (e.g., REVEALPLAQUE) moving beyond simple scores to granular, automated plaque characterization.

Integrating Advanced Hardware and Deep Learning

Clinical Takeaways


1 Visualization over Probability

CAC transforms risk from statistical guessing to direct disease measurement.



2 Context is King

The "Power of Zero" is strong in the asymptomatic, but dangerous in the symptomatic (beware soft plaque).




3 The Athletic Paradox

Lifelong endurance athletes may have higher CAC. Treat the risk factors, but acknowledge the fitness benefit.




4 The Right Tool

Use CAC for asymptomatic risk stratification; use CCTA for symptom evaluation.



References



1. Parikh P, et al. Cleve Clin J Med. 2018.
2. De Bosscher R, et al. Eur Heart J. 2023. (Master@Heart)
3. Blaha MJ, et al. Circ Cardiovasc Imaging. 2023.
4. Grundy SM, et al. Circulation. 2019.
5. Hecht HS, et al. Circulation. 2024.
6. Kim KP, et al. Arch Intern Med. 2009.
7. Bild DE, et al. Am J Epidemiol. 2002. (MESA)
8. Villines TC, et al. J Am Coll Cardiol. 2011. (CONFIRM)
9. Mortensen MB, et al. JAMA Cardiol. 2022.
10. Yu YT, et al. Int J Cardiovasc Imaging. 2021.
11. Aengevaeren VL, et al. JAMA Cardiol. 2019.
12. Willemink MJ, et al. J Cardiovasc Comput Tomogr. 2023.
13. Mergen V, et al. Br J Radiol. 2023.
14. Narula J, et al. Eur Heart J Cardiovasc Imaging. 2024.